CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- 4 Open-market sale Chief Scientific Officer sold 3,155 shares at $15.17 ($47,861)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Principal Accounting Officer sold 2,062 shares at $4.45 ($9,174)
- 4 Open-market buy Director bought 10,000 shares at $5.84 ($58,383)
- 4 Grant or award Chief Business & Legal Officer acquired 36,000 shares (grant or award)
- 4 Grant or award Principal Accounting Officer acquired 11,850 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 36,000 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 30,000 shares (grant or award)
- 4 Grant or award President & CEO acquired 128,000 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 36,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale 10% owner sold 157,895 shares at an average $9.44 ($1,491,041)
- 4 Open-market sale 10% owner sold 1,132,566 shares at $6.53 ($7,395,203)
Page 3 of 9 · 171 filings